<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2024-857
Date of Submission: 2024-12-14

This report was submitted by a Physician from Hayes-Hall Medical Center concerning patient ANON-PX-3679. The subject is an adult male with a significant medical history including migraines, chronic kidney disease, type 2 diabetes, seasonal allergies. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities. 

Current medication review revealed the following suspected agent(s): Omeprazole (Proton-pump inhibitor) administered via the Oral route at a dosage of 295mg, initiated on 2024-10-22 for Gastroesophageal reflux disease with the course ongoing; Metformin (Biguanide) administered via the Intramuscular route at a dosage of 73mg, initiated on 2024-10-22 for Type 2 diabetes with the course ongoing.

On approximately 2024-10-30, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Maculopapular Rash, Diarrhea. The Maculopapular Rash was classified as Severe in severity. This necessitated clinical intervention. The documented action was: Prescribed shoulder and advised economic. The current patient status regarding this symptom is 'Fatal'. The Diarrhea was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovering'. 

CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 7 was calculated, The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Not applicable'. The on-site pharmacist concurred with the assessment during a routine case review. 

Reporter's Narrative Summary: Scene vote action performance family simple daughter. Grow receive security home.</data>
report_id: ADR-2024-857
report_date: '2024-12-14'
patient_details:
  patient_id: ANON-PX-3679
  gender: Male
  relevant_history:
  - migraines
  - chronic kidney disease
  - type 2 diabetes
  - seasonal allergies
suspected_drugs:
- drug_name: Omeprazole
  dosage: 295mg
  route_of_administration: Oral
  start_date: '2024-10-22'
  indication_for_use: Gastroesophageal reflux disease
  drug_class: Proton-pump inhibitor
- drug_name: Metformin
  dosage: 73mg
  route_of_administration: Intramuscular
  start_date: '2024-10-22'
  indication_for_use: Type 2 diabetes
  drug_class: Biguanide
adverse_reactions:
- symptom_name: Maculopapular Rash
  onset_date: '2024-10-30'
  severity: Severe
  outcome: Fatal
  intervention_required: true
  intervention_details: Prescribed shoulder and advised economic.
- symptom_name: Diarrhea
  onset_date: '2024-10-30'
  severity: Life-threatening
  outcome: Recovering
  intervention_required: false
causality_assessment:
  assessment_conclusion: Probable
  dechallenge_rechallenge: Not applicable
  naranjo_score: 7
reporting_facility: Hayes-Hall Medical Center
reporter_type: Physician
notes: Scene vote action performance family simple daughter. Grow receive security
  home.
